Personalis, Inc. Hits New 52-Week High at $16.13, Up 1039% Year-Over-Year

Personalis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 16.13 on July 13, 2026. This achievement marks a remarkable increase from its 52-week low of USD 3.84, reflecting a substantial year-over-year performance of 1039.39%. With a market capitalization of USD 663 million, Personalis operates in a competitive industry that has seen the S&P 500 rise by 20.06% over the same period. The company's financial metrics indicate a challenging landscape, with a negative return on equity of -31.12% and a debt-to-equity ratio of -0.88. Additionally, the stock does not offer a dividend yield, and its price-to-book ratio stands at 2.54. This notable price movement underscores the dynamic nature of the biotechnology market and highlights Personalis, Inc.'s position within it. As the company continues to navigate its operational landscape, this new high serves as a key indicator of its recent performance trajectory.